A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis
K Weisel, S Berger, K Thorn, PC Taylor… - Arthritis research & …, 2021 - Springer
Background Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation
through cell death and proinflammatory cytokine production. This multicenter, randomized …
through cell death and proinflammatory cytokine production. This multicenter, randomized …
Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
T KATSUMOTO, L CHINN, A Morimoto, DJ HADDON - 2020 - Google Patents
WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-
methyl-4-(oxetan-3-yl) piperazin-1-yl] pyridin-2-yl] amino]-6-oxopyridin-3-yl] pyridin-2-yl]-7, 7 …
methyl-4-(oxetan-3-yl) piperazin-1-yl] pyridin-2-yl] amino]-6-oxopyridin-3-yl] pyridin-2-yl]-7, 7 …